---
title: "According to reports, pharmaceutical companies will raise the prices of 350 drugs in the United States next year, with an average increase of 4%"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/271227196.md"
description: "According to data from healthcare research firm 3 Axis Advisors, despite facing price reduction pressures from the U.S. government, pharmaceutical companies plan to raise the prices of at least 350 drugs next year, with an average increase of 4%. These drugs include COVID-19 vaccines, respiratory syncytial virus vaccines, shingles vaccines, and the blockbuster cancer treatment Ibrance. Compared to last year, the number of drug price increases planned for 2026 has increased, with over 250 drugs announced for price hikes last year"
datetime: "2025-12-31T14:25:13.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/271227196.md)
  - [en](https://longbridge.com/en/news/271227196.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/271227196.md)
---

# According to reports, pharmaceutical companies will raise the prices of 350 drugs in the United States next year, with an average increase of 4%

According to data from healthcare research firm 3 Axis Advisors, despite pressure from the U.S. government to lower prices, pharmaceutical companies plan to raise the prices of at least 350 brand-name drugs in the U.S., including COVID-19 vaccines, respiratory syncytial virus vaccines, shingles vaccines, and the blockbuster cancer treatment Ibrance.

The research indicates that the number of drug price increases in 2026 has risen compared to the same period last year, when manufacturers announced price hikes for over 250 drugs; this year's median price increase for drugs is approximately 4%, which is consistent with last year

### Related Stocks

- [300142.CN](https://longbridge.com/en/quote/300142.CN.md)
- [688185.CN](https://longbridge.com/en/quote/688185.CN.md)
- [06185.HK](https://longbridge.com/en/quote/06185.HK.md)
- [603392.CN](https://longbridge.com/en/quote/603392.CN.md)

## Related News & Research

- [CanSinoBIO: From Profit Turnaround to Value Realization as an Innovative Vaccine Leader](https://longbridge.com/en/news/281103901.md)
- [Lupin bets big on India's GLP-1 market & respiratory drugs](https://longbridge.com/en/news/287021542.md)
- [00:45 ETAraceli Biosciences Launches Endeavor® Live Cell for Ultra-High-Throughput Kinetic Imaging in AI-Driven Drug Discovery](https://longbridge.com/en/news/287006505.md)
- [Phase 3-ready cancer biotech Parabilis Medicines files for a $100 million IPO](https://longbridge.com/en/news/286972125.md)
- [Spago Nanomedical Presents Tumorad(R) Clinical Data at the International ANZSNM 2026 Conference](https://longbridge.com/en/news/286726324.md)